FDA — authorised 16 June 2019
- Marketing authorisation holder: MSD MERCK CO
- Status: approved
🇺🇸 Recarbrio in United States
FDA authorised Recarbrio on 16 June 2019
Marketing authorisations
FDA — authorised 16 July 2019
- Application: NDA212819
- Marketing authorisation holder: MSD MERCK CO
- Local brand name: RECARBRIO
- Indication: POWDER — INTRAVENOUS
- Status: approved
Recarbrio in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Infectious Disease approved in United States
Frequently asked questions
Is Recarbrio approved in United States?
Yes. FDA authorised it on 16 June 2019; FDA authorised it on 16 July 2019.
Who is the marketing authorisation holder for Recarbrio in United States?
MSD MERCK CO holds the US marketing authorisation.